CHRONIC HEPATITIS B

This early-stage study tested a DNA vaccine for safety in 10 adults with chronic hepatitis B who did not respond to standard treatments. The goal was to see if the vaccine could safely boost the body's immune response against the virus. The study focused on safety and immune syst…

This study tested a DNA vaccine in 70 adults with chronic hepatitis B who had undetectable virus levels while on antiviral drugs. The goal was to see if the vaccine could train the immune system to keep the virus under control after stopping medication. Researchers measured how l…

This study tested a new medicine called bepirovirsen in 981 adults with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if bepirovirsen could suppress the virus enough to allow patients to stop all hepatitis B treatments and stay virus-free…

This study tested an experimental drug called VIR-2218, given alone or with another medicine (peginterferon), in 84 adults with chronic hepatitis B. The goal was to see if the drug is safe and can reduce the virus in the body. While it aims to control the infection, it is not exp…

This early-stage study tested a new medicine called BW-20507 in 32 people. First, healthy volunteers received a single dose to check safety. Then, people with chronic hepatitis B received multiple doses to see if the drug is safe and how it works against the virus. The main goal …

This early-stage study tested a new oral drug called AB-101 in 128 people. The goal was to check its safety and how the body processes it. First, healthy volunteers received single or multiple doses. Then, people with chronic hepatitis B received multiple doses. The drug works by…

This study tested a new medicine, RBD1016, in 48 adults with chronic hepatitis B who were already taking standard antiviral pills. The goal was to see if the drug is safe and can lower a key virus marker (HBsAg) in the blood. Results will help decide if larger studies are needed.

This early-stage study tested a new oral drug called ALG-000184 in 165 people, including healthy volunteers and patients with chronic hepatitis B. The main goals were to check if the drug is safe and well-tolerated, and to see if it can lower hepatitis B virus levels in the blood…

This study tested a new drug called AB-729, given together with standard antiviral pills and short courses of interferon, in 43 adults with chronic hepatitis B. The goal was to see if the combination could safely lower virus markers in the blood and allow some participants to sto…

This study tested two experimental vaccines, GS-2829 and GS-6779, in 83 healthy volunteers and people with chronic hepatitis B. The main goal was to check safety and side effects, not to cure the disease. Researchers also looked at whether the vaccines boosted the body's immune r…

This study tested a new treatment called VTP-300 combined with a low dose of nivolumab in 121 adults with chronic hepatitis B who were already on antiviral medication. The goal was to see if the combination could lower hepatitis B surface antigen levels more than antivirals alone…

This study measured how often fatty liver and fatty pancreas occur in 217 adults with chronic hepatitis B, comparing those who were obese versus lean. Researchers used a special ultrasound-like test to check for fatty liver and a regular ultrasound for fatty pancreas. The goal wa…